Xvivo Perfusion AB
Extra time: XVIVO extends play for an organ transplant's critical journey
Pioneering technologies that extend the viability of donor organs, ensuring no patient dies waiting
Bull case for Xvivo Perfusion AB
Pioneering ex vivo organ preservation away from just "beer coolers"
XVIVO is well on the way to rolling out machine perfusion that both extend the perservation duration & improve the quality of ex vivo organs
Leverages an established "razor-razorblade" medtech business model
XVIVO's perfusion machines act as the "razor" and their disposables (single-use perfusion containers) act as the recurring revenue "razor blades"
Growth strategy underwritten by profit generation & cash/capital position
Further phases of growth capex (R&D spending) are supported by: current high margin profits; a net cash balance sheet; their 2023 capital replenishment.
Bear case for Xvivo Perfusion AB
Elevated R&D expenses are a mandatory ticket to the game
Investing in new product development & clinical trials requires a lot of upfront R&D cost expense, which is often matched to longer dated revenue streams
Regulatory approvals dictate revenue growth timeframes
The critical nature of organ preservation entails an extensive trial/testing process and a high level of uncertainty around product approval timelines
Medtech sector's growth multiple is threatened by industry & macro risks
Via a lack of progress improving organ transplant utilisation, by competition in the ex vivo organ preservation space, or by government austerity risk to healthcare funding